Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Not yet recruiting 1Approved for marketing 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioma 1Astrocytoma 1

Interventions

Temozolomide 7Radiotherapy 6Specimen Handling 5Magnetic Resonance Spectroscopy 5Radiation 4Radiotherapy, Intensity-Modulated 2Nivolumab 2vorasidenib 1veliparib 1trametinib 1tocilizumab 1pembrolizumab 1fimepinostat 1dabrafenib 1atezolizumab 1abemaciclib 1Vorinostat 1Vincristine 1Spinal Puncture 1Radiotherapy, Conformal 1Protons 1Proton Therapy 1Procarbazine 1OKN 007 1Mycophenolic Acid 1Lomustine 1Irinotecan 1Ipilimumab 1Immunoglobulin G 1Disulfides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Astrocytoma × vorasidenib × Clear all
NCT05484622 2026-03-12

Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma

Servier

Phase 1 Active not recruiting
60 enrolled
CNS

Astrocytoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡